The impact of the prevention programme of hepatitis C over more than a decade: the French experience

J Viral Hepat. 2010 Jun;17(6):435-43. doi: 10.1111/j.1365-2893.2009.01196.x. Epub 2009 Sep 23.

Abstract

To assess the impact of the French national hepatitis C prevention programme initiated in 1999, we analysed trends in hepatitis C virus (HCV) prevalence, testing and characteristics of HCV-infected patient at first referral from 1994 to 2006. We used four data sources: Two national population-based sero-prevalence surveys carried out in 1994 and 2004; two surveillance networks, one based on public and private laboratories throughout France and the other on hepatology reference centres, which aim to monitor, respectively, trends of anti-HCV screening and of epidemiological-clinical characteristics of HCV patients at first referral. Between 1994 and 2004, the anti-HCV prevalence for adults aged 20-59 years decreased from 1.05 (95% confidence interval 0.75-1.34) to 0.71 (0.52-0.97). During the same period, those anti-HCV positive with detectable HCV RNA decreased from 81 to 57%, whereas, the proportion of anti-HCV positive persons aware of their status evolved from 24 to 56%. Anti-HCV screening activity increased by 45% from 2000 to 2005, but decreased in 2006 (-10%), while HCV positivity among those tested decreased from 4.3 to 2.9%. The proportion of cirrhosis at first referral remains around 10% between 2001 and 2006, with many patients with excessive alcohol consumption (34.7% among males) or viral co-infections (HIV seropositivity for 5.2% patients). Our analysis indicates that the national programme had a positive impact at the population level through improved prevention, screening and management. There is still a need to identify timely those at risk for earlier interventions, to assess co-morbidities better and for a multidisciplinary approach to HCV management.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Alcoholism / epidemiology
  • Communicable Disease Control / methods*
  • Comorbidity
  • Female
  • France / epidemiology
  • HIV Infections / epidemiology
  • Hepatitis C / complications
  • Hepatitis C / epidemiology*
  • Hepatitis C / prevention & control*
  • Hepatitis C Antibodies / blood*
  • Humans
  • Liver Cirrhosis / epidemiology
  • Liver Cirrhosis / virology
  • Male
  • Middle Aged
  • RNA, Viral / blood
  • Seroepidemiologic Studies
  • Young Adult

Substances

  • Hepatitis C Antibodies
  • RNA, Viral